Back

Empagliflozin preserves hemodynamics and left ventricular function in nephrectomized rats after ischemia-reperfusion injury: a potential direct cardioprotective effect of SGLT2 inhibitor

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction Drugs, Drug Targets ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Kei Akiyoshi

Kasukabe Chuo General Hospital, Kasukabe (Japan)

6 More presentations in this session

Presentation thumbnail
PPAR alpha-driven CISD2 upregulation by hesperetin protects against myocardial ischemia/reperfusion injury
Professor C. Yeh (Tao-Yuan, TW)
Abstract Slides Video
Presentation thumbnail
Organic polydopamine nanoparticles ameliorate endothelial ischemia-reperfusion injury, increasing antioxidant defense and reducing inflammatory response
Doctor S. Babboni (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Activation of AMPK via inhibition of PAR2 limits myocardial ischemia-reperfusion injury
Doctor L. Li (Winnipeg, CA)
Abstract Slides Video
Presentation thumbnail
Novel first-in-class drug candidate protects from ischemia-reperfusion injury by targeting the SERCA2 complex
Mrs A. Calejo (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Mitochondria-targeted Hydrogen Sulfide exerts protective effects and maintains mitochondria homeostasis against ischemia reperfusion injury in heart transplantation via the mitofusion-1 pathway
Doctor C. Zhu (Changchun, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Innovative therapeutic strategies to combat ischaemia-reperfusion injury and cardiac dysfunction

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study
thumbnail
Congress Presentation
Mechanistic insights of SGLT2 inhibitors effectiveness
thumbnail
Congress Presentation
Empagliflozin improves metabolic profile and prevents myocardial and coronary dysfunction in diabetic rat hearts subjected to ischemia/reperfusion injury

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources